According to the latest National Comprehensive Cancer Network (NCCN) guidelines, the first-line therapy for treatment, naïve ALK-positive NSCLC typically involves alectinib, brigatinib, or lorlatinib [3]. In cases where patients exhibit disease progression despite initial therapy, options include definitive radiation therapy (RT), switching to another second or third-generation ALK inhibitor, or assessing for specific resistance mutations, such as the ALK G1202R mutation, to guide treatment selection [3]. Here, ALK is linked to non-small cell lung carcinoma.